Last week saw the newest full-year earnings release from Knight Therapeutics Inc. ( TSE:GUD ), an important milestone...
Knight Therapeutics ( TSE:GUD ) Full Year 2023 Results Key Financial Results Revenue: CA$328.2m (up 12% from FY 2022...
Achieved Record Annual Revenues and EBITDAMONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2023. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. 2023 Highlights Financial results Revenues were $328,199, a